Screener
Polaryx Therapeutics, Inc. PLYX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Polaryx Therapeutics, Inc.’s 10-Q, filed May 15, 2026.
- Filed
- May 14, 2026, 8:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-056973
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development expenses | $679 | $4,716 |
| General and administrative expenses | 1,279 | 336 |
| Total operating expenses | 1,958 | 5,052 |
| Operating loss | (1,958) | (5,052) |
| Other expense – direct listing offering costs | (586) | — |
| Net loss and comprehensive loss | $(2,544) | $(5,052) |
| Net loss per share – basic and diluted | $(0.05) | $(0.11) |
| Weighted average common shares outstanding – basic and diluted | 47,219,329 | 44,338,960 |
Item 1. Financial Statements (Unaudited) Item 1. Financial Statements
FAQ
- What is Polaryx Therapeutics, Inc.'s net income?
- Polaryx Therapeutics, Inc. (PLYX) reported net income of -$2.54M in Q1 2026.
- How has Polaryx Therapeutics, Inc.'s net income changed year-over-year?
- Polaryx Therapeutics, Inc.'s net income increased by 49.6% year-over-year, from -$5.05M to -$2.54M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Polaryx Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude